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Objective: To investigate whether nitric oxide participate in the cardiovascular function 27 
and haemodynamic adaptation to acute hemorrhage in animals with thyroid disorders. 28 
Materials/Methods: Sprague-Dawley rats aged 2 months old treated with T3 (Hyper, 29 
20ug/100g body weight) or 0.02% methimazole (hypo, w/v) during 28 days were 30 
pretreated with N
G 
nitro-L-arginine methyl ester (L-NAME) and submitted to 20% 31 
blood loss. Heart function was evaluated by echocardiography. Measurements of arterial 32 
blood pressure, heart rate, nitric oxide synthase activity and protein levels were 33 
performed. Results: Hypo decreased fractional shortening and ejection fraction and 34 
increased left ventricle internal diameter. Hyper decreased ventricle diameter and no 35 
changes in cardiac contractility. Hemorrhage elicited a hypotension of similar 36 
magnitude within the 10 min. Then, this parameter was stabilized at about 30-40 min 37 
and maintained until finalized 120 min. L-NAME rats showed that the immediate 38 
hypotension would be independent of nitric oxide. Nitric oxide synthase inhibition 39 
blunted the changes of heart rate induced by blood loss. Hyper and hypo had lower 40 
atrial enzyme activity associated with a decreased enzyme isoforms in hypo. In 41 
ventricle, Hyper and hypo had a higher enzyme activity which was not correlated with 42 
changes in protein levels. Hemorrhage induced an increase heart nitric oxide 43 
production. Conclusions: Thyroid disorders were associated with hypertrophic 44 
remodelling which was and impacted differently on cardiac function and  its adaptation 45 
to a hypovolemia. Hypovolemia triggered a nitric oxide synthase activation modulating 46 
the heart function to maintain haemodynamic homeostasis. This involvement depends 47 








Hypovolemia, secondary to major blood loss, frequently precedes multiple organ 53 
dysfunctions (De Santis and Singer 2015). Activation of several neurohormonal factors 54 
(nitric oxide [NO], catecholamines, endothelins, vasopressin, renin-angiotensin system) 55 
is involved in the restoration of vascular volume and blood pressure following bleeding 56 
(Fujisawa et al. 1999; Paczwa and Ganten 1999).  This adaptive response to the decrease of the 57 
total blood volume implies a peripheral vasoconstriction which induces a redistribution of blood 58 
flow to the vital organs within which highlights the heart (Schadt and Hasser 2004). 59 
Previously, we demonstrated that hypovolemic state induced by acute hemorrhage 60 
provoked a heterogeneous and dynamic NO synthase (NOS) activation modulating the 61 
cardiovascular response in young rats. Increased cardiac endothelial NOS expression is 62 
an early molecular response to regulate cardiac function after blood loss. Inducible NOS 63 
becomes a major source of cardiac NO production in later stages, which could be 64 
determinant of heart dysfunction after 120 min of sustained hemorrhagic shock
 
65 
(Balaszczuk et al. 2006). 66 
On the other hand, it is well known that cardiovascular function is also influenced by 67 
the autonomic nervous system and numerous endocrine hormones in which thyroid 68 
hormones have relevance.  Thyroid hormone deficiencies, as well as excesses, result in 69 
profound changes in cardiac function regulation and cardiovascular haemodynamia 70 
mediated by genomic and non-genomic effects (Vargas-Uricoechea et al. 2014). A 71 
functional relation involving thyroid hormones, endothelial cells and NO has been 72 
extensively described in the past last years. There are several studies that showed that 73 
thyroid hormones and NO are involved in many different signaling pathways related 74 
with normal postnatal cardiac development, maturation and function (Lepic et al. 2006). 75 
We have previously demonstrated that thyroid hormones are able to regulate intrinsic 76 
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heart rate (HR) in a heart without autonomic regulation. According to our results, NO 77 
pathway would be involved in this mechanism. Thyroid hormones modulate NO steady-78 
state level which may act as a messenger to modulate the mitochondrial bioenergetic 79 
function, resulting in an NO-mediated regulation of the heart pacemaker activity (Fellet 80 
et al. 2004, 2006, 2008). Additionally, we demonstrated that hypothyroidism 81 
contributes in a differential way to aging-induced changes in the myocardium and aorta 82 
tissues. Low thyroid hormones levels would enhance the aging effect on the heart 83 
related to cardiac NO production (Sarati et al. 2012). We also revealed that the heart of 84 
male and female rats undergoes distinct adaptive responses to hyperthyroidism that 85 
confer to the latter a relatively stronger adaptation profile that appears to be related to 86 
the ability to regulate NO production (Rodriguez et al. 2015).  87 
Considering that thyroid status alterations are one of the major endocrine diseases in 88 
adulthood and its association with a significant increase of cardiovascular risk in the 89 
middle-aged, the aim of the present work was to analyze whether changes in NO 90 
signalling participate in the cardiovascular manifestations of thyroid disorders and 91 
whether these changes are involved in haemodynamic adaptation to acute hemorrhage 92 
in animals with thyroid disorders.  93 
 94 
Materials and methods  95 
Animals 96 
Male Sprague–Dawley rats 2 months old from the breeding laboratories of the 97 
“Facultad de Farmacia y Bioquímica” (Universidad de Buenos Aires, Argentina) were 98 
used throughout the study. Rats were housed in humidity- and temperature- controlled 99 
environment with an automatic 12/12-h light/dark cycle. Rats were fed standard rat 100 
chow from Ganave (Buenos Aires, Argentina) and received tap water ad libitum up to 101 
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the day of the experiments. All procedures were reviewed and approved by the National 102 
Food, Drug and Medical Technology Administration (ANMAT), National Department 103 
of Health and Environment, Argentina (No. 6344/96).  104 
Rats were randomly assigned to one of the three groups  105 
Control rats (Eut, n=15): euthyroid animals who received s.c. injections of 0.9% NaCl 106 
(0.1 ml/100 g body weight (BW) every 2
nd
 day during 28 days.   107 
T3-treated rats (Hyper, n=15): animals received s.c. injections of T3 (Sigma, 20ug/100g 108 
body weight) every 2
nd
 day during 28 days (Heron and Rakusan, 1996).   109 
Methimazole-treated rats (hypo, n=15): animals were rendered hypothyroid after 28 110 
days of treatment with 0.02% methimazole (w/v) in the drinking water (Franco et al. 111 
2006).  112 
 113 
Determination of treatment efficacy 114 
In order to confirm the hypo and hyperthyroid states, serum thyroid-stimulating 115 
hormone (TSH), total triiodothyronine (T3) and thyroxin (T4) (TSH kit, National 116 
Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 117 
Bethesda, USA) were measured by radioimmunoassay at the beginning and the end of 118 
the experimental period. Intra- and inter-assay coefficients of variation for TSH were 119 
8.7% and 13.4%, respectively (Greeley et al. 1982). T3, inter- and intra-assay 120 
coefficients of variation varied from 4.2 to 6.0 and 5 to 6. 5% respectively; T4 inter- and 121 
intra-assay coefficients of variation varied from 7.1 to7.4 and 2.9 to 5.1% respectively). 122 
 123 
Echocardiographic measurements   124 
After 28 days of treatment, or control period, rats were anesthetized with urethane (1.0 125 
g/kg, ip), their chests were shaved under aseptic conditions and echocardiographic 126 
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measurements were performed in the left lateral decubitus position. Two-dimensional 127 
directed M-mode images were obtained using a Sonoscape (A6 Vet) system with a 9-4 128 
MHz transducer. Measurements were taken in the right parasternal short axis plane at 129 
the level of the mitral valve leaflets. LV internal diameter (LVID), LV posterior wall 130 
thickness (PWT) and anterior wall thickness (AWT) were measured in both systole (s) 131 
and diastole (d). Ejection fraction (EF), fractional shortening (FS) and systolic volume 132 
were measured from ventricular internal diameters by the echocardiography system. All 133 
determinations were made according to the guidelines of the American Society of 134 
Echocardiography. Each rat was then instrumented with catheters. Animals were kept 135 
under anesthesia by additional small doses of urethane throughout the experiment. Body 136 
temperature was monitored with a rectal probe and maintained at 37.0 ± 0.5 ºC with 137 
heating lamps to avoid the influence of temperature on cardiovascular parameters 138 
during the experiment.  139 
 140 
Cardiovascular assessments in thyroid desorders  141 
After 28 days of treatment, the animals were anesthetized with urethane (1,0 g/kg ip). 142 
To ensure an open airway, a tracheotomy was performed using polyethylene tubing (3.5 143 
or 4 mmID, Portex). Mean arterial pressure (MAP) was measured through a cannula 144 
inserted in the right femoral artery and connected to a pressure transducer (Statham P23 145 
ID, Gould Inst., Cleveland, OH, USA); measurements were recorded with a polygraph 146 
(Physiograph E & M, Houston, TX, USA) during the whole experiment. Heart rate 147 
(HR) was determined from the pulsatile pressure signal by beat-to-beat conversion with 148 
a tachograph amplifier (model S77-26 tachometer, Coulbourn Instruments, Allentown, 149 
PA, USA). The Labtech Notebook program (Laboratory Technology, Wilmington, MD, 150 
USA) was used for data acquisition.  151 
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Experimental protocol  152 
Eut, Hyper and hypo animals were subdivided into two experimental groups:  153 
1) Hemorrhaged rats (H). After a 30-min stabilization period, basal values were 154 
measured over a 5-min period. Subsequently, the acute hemorrhage was performed. 155 
Thereafter, hemodynamic parameters were continuously recorded over a 120-min 156 
period after the bleeding (n=15 each group). 157 
2) Hemorrhage + L-NAME (H+LNAME): After a 30-min stabilization period, basal 158 
values were measured over a 5-min period. Later, the animals received an infusion of 159 
N
G 
nitro-L-arginine methyl ester (L-NAME, 0,5 mg/kg/h IV = 100 µl/h), which was 160 
maintained during the experimental period. Subsequently, the acute hemorrhage was 161 
performed. Thereafter, hemodynamic parameters were continuously recorded over a 162 
120-min period after the bleeding (n=15 each group). 163 
The hypovolemic state in H and H+LNAME groups was induced through an acute 164 
hemorrhage using a cannula inserted in the left femoral artery (Riviero, PR10). The 165 
bleeding was done by a loss of 20% of the blood volume during 2 minutes, at constant 166 
flux. The volume was calculated individually for every animal, from the total blood 167 
volume (7% of the body mass).  168 
The L-NAME, an unspecific inhibitor of the NOS, was administrated as a continual 169 
infusion through a cannula inserted in the right femoral vein (Riviero PR 10, 0,5 170 
mg/kg/h IV = 100 µl/h). 171 
At the end of each experimental protocol, rats were sacrificed by pneumothorax and 172 
heart was removed. Western blot analysis for NOS was performed in this tissue, and 173 
NOS activity was measured according to the method of the conversion of [14C (U)]-L-174 
arginine to [14C (U)]-L-citrulline.  175 
 176 
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Nitric oxide synthase activity 177 
Capacity for cardiac NO formation was assessed determining NOS activity in right atria 178 
and left ventricle from Eut, Hyper and hypo animals by measuring the conversion of 179 
[14C (U)]-L-arginine to [14C (U)]-L-citrulline. Tissue homogenates (approximately 50 180 
µg protein) were incubated in Tris-HCl buffer (pH 7.4) containing 1 µg/mL L-arginine, 181 
[14C (U)]-L-arginine (346 µCi/mL), L-valine (67 mM), NADPH (1 mM), calmodulin 182 
(30 nM), tetrahydrobiopterin (5 µM) and CaCL2 (2 mM) for 60 minutes at room 183 
temperature. At the end of the incubation period, the NOS reaction was arrested by 184 
addition of a buffer solution containing 20 mM HEPES buffer and 20 mM EDTA, pH 185 
5.5. Reaction mixtures were loaded onto cation exchange columns (Dowex AG 50W-186 
X8, Na+ form; Bio-Rad) and [14C (U)]-L-citrulline was eluted from columns with 0-50 187 
ml ddH2O. The amount of [14C (U)]-L-citrulline eluted was quantified using a liquid 188 
scintillation counter (Wallac 1414 WinSpectral; EG&G Company, Turku, Finland) as 189 
described previously (Sarati et al. 2012). All compounds, except [U-14C]-L-arginine 190 
monohydrochloride (346mCi/mmol, Amersham Life Science), were purchased from 191 
Sigma Chemic. Protein determination was made using the Lowry method, with bovine 192 
serum albumin as a standard.  193 
Calcium dependence  194 
In order to determine calcium dependence, atria and ventricle NOS activity was 195 
determined using [U-14C] arginine as substrate as described above. Tissue slices (2-3 196 
mm thick) from Eut, hypo and Hyper animals were obtained. Some slices from 197 
haemorrhaged groups were preincubated (15 min) with calmidazolium (Cz, 1µM) 198 
(Elesgaray et al. 2008) before incubation with [U-14C] L-arginine during 30 minutes at 199 
37 ºC. The amount of [14C] L-citrulline obtained was determined with a liquid 200 
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scintillation counter. Nitric oxide production (measured as pmol of [14C] citrulline) was 201 
expressed in pmol/g wet weight min.   202 
 203 
Western blot analysis  204 
The right atria and left ventricle samples were homogenized on ice with a Tissue Tearor 205 
(Biospec Products) in homogenization buffer (50 mmol/L Tris, 0.1 mmol/L EDTA, 0.1 206 
mmol/L EGTA, 1% Triton, 1 mmol/L PMSF, 1 µmol/L pepstatin, 2 µmol/L leupeptin, 207 
1× protease inhibitor cocktail from Roche Diagnostics). Protein concentration in the 208 
Triton-soluble supernatant was determined using the Lowry assay. Equal amounts of 209 
protein (100 µg protein/lane) were separated by electrophoresis in 7.5% SDS-210 
polyacrylamide gels (Bio-Rad, Munich, Germany), transferred to a nitrocellulose 211 
membrane (Bio-Rad) and then incubated with rabbit polyclonal anti-NOS antibodies,  212 
diluted at 1:500. The primary antibodies were: polyclonal rabbit anti-inducible NOS 213 
(iNOS) (epitope at the carboxy terminus), anti-endothelial NOS (eNOS) (epitope at the 214 
amino terminus) and anti-neuronal NOS (nNOS) (epitope at the amino terminus). 215 
Finally, a secondary immunoreaction with a goat anti-rabbit antibody conjugated with 216 
horseradish peroxidase (dilution 1:5000) was performed. Samples were revealed by 217 
chemiluminescence using Kalium reagent for 2–4 min. Density of the respective bands 218 
was quantified by densitometric scanning of Western blots using a Hewlett-Packard 219 
scanner and Totallab analyzer software (Biodynamics, Seattle, WA, USA), and protein 220 
amounts were calculated by comparison to the densitometric values of the 221 
corresponding standard. Protein levels were expressed as a ratio of the optical densities 222 
of NOS isoforms and β-actin band (using anti-beta actin, clone EP1123Y, rabbit 223 
monoclonal antibody) to check for any inaccuracies in protein loading. 224 
 225 




The antibodies against the three isoforms of NOS (iNOS (610333), eNOS (610298) and 227 
nNOS (610311) were supplied by BD Biosciences and anti β-actin by Millipore (04-228 
1116). Secondary antibody (170-6515) was by Bio-Rad laboratories. The Western Blot 229 
Detection System was supplied by Amersham Pharmacia Biotech. Biochemicals were 230 
supplied by Sigma Chemical (Saint Louis, MO, USA).  231 
 232 
Ethical approval for animal experimentation 233 
Animals were cared for according to regulation 6344/96 of Argentina's National Food, 234 
Drug and Medical Technology Administration (ANMAT). Experiments with animals 235 
had been performed in accordance with UK legal requirements. Experimental 236 
procedures were approved by the ethics committee of the Facultad de Farmacia y 237 
Bioquímica (CICUAL; EXP UBA N° 0054570), Universidad de Buenos Aires, 238 
Argentina. 239 
 240 
Statistical analysis 241 
Data in tables and figures are mean values ± SEM. Data were evaluated with univariate 242 
and multivariate approaches for a completely randomized design, with a structure of 243 
two factors (hemorrhage and thyroid hormones). For each variable, ANOVA or 244 
MANOVA analysis was performed when appropriate. The Levene's and Shapiro–Wilk's 245 
tests were used to evaluate homogeneity of variances and normality of data, 246 
respectively. 247 
When normality and homogeneity of variances assumptions were satisfied, the 248 
Bonferroni multiple comparison test was run. In the case of non-homogenous variances, 249 
a multiple comparison test, such as Tamhane, was run. To detect association among 250 
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variables, a correlation analysis was performed and the Pearson coefficient was 251 
calculated. All statistical procedures were performed using the SPSS statistical software 252 
package version 22.0 statistical significance was set at P<.05. 253 
 254 
Results 255 
Treatment efficacy  256 
Treatment with methimazole and T3 was effective in establishing a hypothyroid and 257 
hyperthyroid state, respectively. TSH plasmatic levels were higher and lower in hypo 258 
and Hyper rats respectively than Eut animals. T3 and T4 levels decreased in hypo rats, 259 
while T4 increased in Hyper animals. Body weights were similar in the three groups of 260 
animals. Basal MAP values were similar in Eut, hypo and Hyper rats. However, basal 261 
HR values were lower and higher in hypo and Hyper rats compared with Eut animals, 262 
respectively (Table 1).  263 
 264 
Echocardiographic measurements 265 
Table 1 also shows echocardiographic data for all groups. LV systolic and diastolic 266 
chamber diameters increased in hypo rats meanwhile these diameters decreased in 267 
Hyper animals. LV anterior and posterior wall thickness in both systole and diastole 268 
remained unchanged between Eut and Hyper animals; however, a reduction in these 269 
parameters was observed in hypo group. LV ejection fraction and fractional shortening 270 
did not change between Eut and Hyper animals but they were reduced both in  271 
hypothyroid state. Figure 1 shows representative images of M-mode echocardiographic 272 
tracing.  273 
 274 
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Changes in systemic hemodynamic parameters during and after hemorrhagic state  275 
Figure 2 illustrates the time course of MAP and HR during 120 min after bleeding. 276 
Baseline MAP (mm Hg) measurements were not different among the three groups of 277 
rats. Hemorrhage induced a marked decrease in MAP in Eut group, which reached a 278 
value of 44±4 mm Hg at 10 min following the bleeding period (P<0.001 versus basal 279 
values), with subsequent stabilization at about 55±4 mm Hg at 35 min (P<0.01 versus 280 
basal values). The pressure response to bleeding was similar in the three experimental 281 
groups. However, the magnitude of immediate hypotension after bleeding was greater in 282 
animals with thyroid alterations. The pressure remained low during the entire 283 
experimental time presenting lower values of animals with thyroid disorders (panel A).  284 
L-NAME treatment has not altered basal MAP in the three experimental groups. Blood 285 
pressure in L-NAME Eut treated rats group was 37 mm Hg (P<0.01 versus basal values) 286 
at 10 min hemorrhage, rising to 82 ± 4 (P=ns), 100 ± 4 (P< 0.01) and 105 ± 4 mm Hg 287 
(P<0.01) during 35, 60 and 120 min, respectively following the bleeding. The inhibition 288 
of NO system induced a recovery of the MAP after bleeding, registering a stabilization 289 
of this parameter to the 60 minutes the hemorrhage, in values higher than hypo and 290 
Hyper animals. In relation to the hypothyroid rats, the L-NAME treatment induced a 291 
greater hypotensive response after bleeding. However, in the later stages, MAP was 292 
gradually increased stabilizing in 53 mmHg at about 65 min. The hyperthyroid animals 293 
presented a lower hypotensive response to the euthyroid, but managed to reach MAP 294 
values close to the baseline at about 100 minutes (panel B).  295 
Panel C illustrates the time course of the HR in Eut, hypo and Hyper animals after 296 
bleeding. Basal HR of Eut animals was around 352±15 bpm, while that of the hypo and 297 
Hyper rats was 214±15 bpm and 424±13 bpm, respectively. The hemorrhage induced a 298 
bradycardia of short duration followed by a gradual increase in this parameter in all the 299 
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groups. Eut animals have attained the stabilization of this parameter at about 30 minutes 300 
after hemorrhage, whereas this time was between 10-15 minutes to achieve the 301 
stabilization in hypo and Hyper rats (panel C). Treatment with L-NAME annulled the 302 
changes of HR to hemorrhage in Eut and hypo rats. L-NAME Hyper treated animals 303 
showed a similar HR response after withdrawal (panel D). 304 
 305 
Nitric oxide synthase activity and western blot  306 
Figure 3 (panel A) shows that hypo and Hyper animals exhibited a decreased atrial NOS 307 
activity compared with Eut rats. Bleeding increased NOS activity in all groups of 308 
animals. However, the magnitude of change was greater in Eut and Hyper rats 309 
compared with hypo animals. Endothelial NOS isoform decreased in hypo rats (panel 310 
B). There were no differences between Eut and Hyper groups of animals. Hemorrhage 311 
increased eNOS protein levels in Eut and hypo rats. However, Hyper animals showed 312 
decreased eNOS protein levels after withdrawal. Inducible and neuronal NOS were 313 
lower in hypo rats compared with Eut group. Inducible and neuronal NOS proteins 314 
levels did not change in Eut and Hyper rats (panels C and D). Bleeding increased iNOS 315 
proteins levels in all groups of animals meanwhile it did not change nNOS protein 316 
levels in experimental groups (panel C and D).  317 
Figure 4 (panel A) shows that hypo and Hyper rats showed increased left ventricle NOS 318 
activity compared with Eut animals. Hemorrhage increased NOS activity in all groups 319 
of animals. eNOS, iNOS and nNOS proteins levels did not change with thyroid status. 320 
Bleeding increased eNOS protein levels in Eut and hypo animals (panel B) and iNOS 321 
proteins levels in Eut rats (panel C). nNOS did not change with hemorrhage (panel D). 322 
Figure 5 (panel A) showed that when NOS activity was evaluated on atria slices, we 323 
obtained similar results to those obtained using homogenates. Hypo and Hyper animals 324 
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exhibited a decreased atrial NOS activity compared with Eut rats and bleeding increased 325 
NOS activity in all groups of animals. Calmidazolium treatment attenuated NOS 326 
activity in Eut and hypo animals without without modification in hyper group of 327 
animals. In ventricle, hypo and Hyper rats showed increased left ventricle NOS activity 328 
compared with Eut animals and hemorrhage increased NOS activity in all groups of 329 
animals. Pretreatment with calmidazolium attenuated and blunted the increase of NOS 330 
activity induced by hemorrhage in Eut and hypo  animals, respectively. The NOS 331 
activity increase after bleeding was not altered by calmidazolium in Hyper animals.   332 
 333 
Discussion 334 
The present study provides new evidences that changes in cardiac function 335 
associated with thyroid disorders and hypovolemia not only involve effects on 336 
sympathetic nervous system, but may also involve changes in the response of the 337 
myocytes to NO bioavailibity. This study investigated the role of NO in the 338 
cardiovascular adaptation following acute hemorrhage in rat with thyroid disorders. 339 
TSH measurements showed that T3 and methimazol treatment were effective to 340 
establish hyper and hypothyroid state, respectively. In our experimental condition, basal 341 
MAP values were similar in the three experimental groups. These findings are 342 
surprising. It would be expected that MAP decreases and increases in hypo and 343 
hyperthyroid state, respectively. However, our results showed that MAP did not change 344 
compared with euthyroid control rats. Maintained pressure values in animals with 345 
thyroid disorders may be due to changes induced on diastolic pressure are similar in 346 
magnitude to the changes induced on systolic pressure despite having very different HR 347 
values.  It is important to consider that this discrepancy with others researchers might be 348 
due to the different duration and degree of hypo and hyperthyroidism developed in our 349 
experimental conditions. Additionally, we have shown that L-NAME infusion did not 350 
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alter basal blood pressure values in experimental groups. It is probable that in this 351 
condition the inhibition of the constitutive NOS activity is only partial, being the 352 
quantity of NO that exceeds sufficient to maintain MAP within the basal range.  353 
 When we evaluated cardiac function associated with thyroid status, 354 
echocardiographic data confirmed that hypothyroid animals have FS and EF decreased 355 
and increased left ventricle internal diameter. This would indicate that myocardial 356 
contractility would be altered and the ventricle would not be filling properly especially 357 
during diastole in these animals. It is important to note that FS depends primarily 358 
afterload. The most common causes of decreased FE in hypothyroidism would be 359 
blockages in the coronary arteries, increased blood pressure, heart rhythm disturbances, 360 
or weakening of the heart muscle. In this context, hypothyroidism could be associated 361 
with increased prevalence of cardiac heart failure associated with thyroid hormones 362 
deficiencies (Biondi 2012). On the other hand, although hyperthyroid animals showed a 363 
decrease in the diameter of the ventricle, no change was observed in cardiac 364 
contractility in our experimental model. Taken together, these results suggest that hypo 365 
and Hyper rats would exhibit different thyroid disorder-induced remodeling adaptation. 366 
Hypothyroidism would exhibit a greater eccentric hypertrophic response while 367 
hyperthyroid animals would exhibit concentric hypertrophic response. These findings 368 
agreed with others authors who described the development of the eccentric hypertrophy 369 
in hypothyroidism (Wang et al. 2010; Sarati et al. 2012 ) and concentric left ventricle 370 
hypertrophy associated with thyrotoxicosis (Basset et al. 1980; Abergel et al. 1995). 371 
The mechanisms of the animal model of thyroid disturbances induced cardiac 372 
hypertrophy are multifactorial. It is not clear whether thyroid hormone status-induced 373 
cardiac hypertrophy results from a direct effect on the heart, alterations of the 374 
adrenergic nervous system signaling, or altered cardiac loading conditions. Taking into 375 
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account the latter, we evaluate cardiovascular hemodynamics changes to hemorrhage in 376 
animals with thyroid disorders. It is well known that cardiovascular adaptation to this 377 
hypovolemic state is under dynamic control of the sympathetic and parasympathetic 378 
divisions, the magnitude of hemorrhage, the rate of bleeding, and the species examined 379 
(Schadt and Ludbrook, 1991). Different circulating endocrine and local paracrine 380 
factors such as NO have been postulated to modulate the cardiovascular response to 381 
hypovolemia (Goldstein et al. 1999). In this study, we showed that hemorrhage elicited 382 
a significant decrease between 50-59% of arterial blood pressure within the 10 min after 383 
bleeding from basal values in all experimental groups. The magnitude of this immediate 384 
hypotension would seem similar in all rats. After this time, this parameter increased 385 
stabilizing its values at about 30-40 min and was maintained until finalized 120 min. 386 
Pretreatment with L-NAME before bleeding induced a similar immediate decrease (at 387 
about 60%) in all experimental groups. This immediate hypotension was followed by a 388 
faster recovery of blood pressure to basal values in euthyroid and hyperthyroid 389 
hemorrhaged rats. This parameter did not reach basal values in hypo rats. Taken 390 
together, these findings suggest that the immediate hypotension would be independent 391 
of NO system, however, after this time (10 min) NO would modulate systemic vascular 392 
response probably due a direct vasodilatory action on vascular smooth muscle 393 
especially in euthyroid and hyperthyroid animals. This effect of NO seems to be lower 394 
in hypothyroidism in which basal values of MAP were not reached. However, we 395 
cannot throw away the effects of NO on the integrated mechanisms which become 396 
activated in response to hemorrhage as well as the release of several neurohormonal 397 
vasoconstrictor factors (catecholamines, endothelins, vasopressin, renin–angiotensin 398 
system) (Fujisawa et al. 1999; Moreno et al. 2002). 399 
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Focusing on chronotropic response, our results showed an increase and decrease 400 
of basal pacemaker activity in hyper and hypothyroid rats compared with respective 401 
euthyroid animal. These changes would confirm the tachycardic action of T3 (Sun et al.  402 
2001).We also showed that NOS inhibition was not modified basal values of HR in the 403 
three groups of animals, but blunted the changes induced by blood loss. Hypovolemic 404 
state provoked after the expected immediate reflex-induced tachycardia, a bradycardic 405 
stage followed by a gradual increase of HR during 120 min (Balaszczuk et al. 2006). It 406 
is known that blood pressure is maintained in the early stage of hemorrhage by reflex 407 
increase in HR, vascular resistance, and peripheral sympathetic nerve activity. The 408 
inhibition of NO system would affect the immediate baroreflex response in our 409 
experimental model. The bradycardia, observed in the early stages, may result from 410 
alterations of the activation of unmyelinated vagal afferents (C fibers) from the left 411 
ventricle induced by the loss of 20% in the blood volume. A decrease of HR may seem 412 
unreasonable during hemorrhage but it could be a part of a complex reflex in order to 413 
reduce an ongoing blood loss by reducing blood pressure by means of peripheral 414 
vasodilatation and, at the same time, maintain organ blood flow. The absence of the 415 
bradycardia suggests that NO could be involved in the cholinergic modulation of HR in 416 
the early stage of hypovolemic state. However, the relationship between the NO system 417 
and the absence of the later increase of HR was not well understood. It was reported that 418 
systemic inhibition of NOS in vivo in humans, by L-NMMA, significantly reduced 419 
renal plasma flow in the absence of alterations in glomerular filtration rate, blood 420 
pressure, or pulse rate (Wolzt et al. 1997). By contrast, Schmetterer et al. (1999) 421 
showed a significant decrease in heart rate after infusion of L-NMMA.  These findings 422 
suggest that nitric oxide, present in the sinoatrial and atrioventricular nodes, seems to 423 
play an important role in pacemaker activity control. The action of L-NAME on the 424 
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later tachycardia may be a primary action due to inhibition of NO pathway or a 425 
secondary effect resulting from the absence of the maintained hypotension after the 426 
hemorrhage. 427 
Considering NO system in the heart, our results showed that animals with 428 
thyroid alterations have a lower atrial NOS activity than Eut rats. This lower activity of 429 
the enzyme is associated with a decrease of the three NOS isoforms protein levels in 430 
hypo rats. Meanwhile, hyperthyroid animals showed no changes in protein levels of the 431 
three isoforms of the enzyme. These findings allow us to think that negative modulators 432 
of the enzyme, like caveolins, are probably increased in hyperthyroidism. 433 
 In addition, a contradictory result was found in the left ventricle. Animals with 434 
thyroid disorders had a higher enzyme activity than euthyroid and this rise was not 435 
correlated with changes in NOS protein levels. Positive modulators of NOS activity 436 
would be exacerbated in thyroid disorder. 437 
Focusing on physiological involvement of NO during hypovolemic state, we 438 
observed that acute hemorrhage results in an excessive production of NO in right atria 439 
as well as in left ventricle at 120 min after blood loss in all experimental groups. In the 440 
atrium, increased NOS activity induced by bleeding could be due to increased 441 
endothelial and inducible isoform of the enzyme in euthyroid and hypothyroid animals 442 
and only iNOS protein levels in hyperthyroidism. Experiments with calmidazolium 443 
confirmed these findings. Conversely, withdrawal induced a decrease in protein levels 444 
of eNOS in hyperthyroidism.  445 
On the other hand, the left ventricle increased NOS activity induced by 446 
hemorrhage could be due to a rise in eNOS protein levels in euthyroid and hypothyroid 447 
animals. Additionally, hypovolemia increased iNOS protein levels in euthyroid rats. 448 
Our results also suggested that the NOS activity changes induced by hypovolemic state 449 
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could involve alteration of positive modulators of the enzyme in hyperthyroidism.  450 
Experiments with calmidazolium confirmed these findings. Calmodulin antagonist 451 
attenuated NOS activity increase in Eut animals meanwhile blunted the rise in hypo rats 452 
and did not modify it in Hyper group.  453 
In summary, the key findings of this study are that thyroid hormones 454 
deficiencies, as well as excesses result in alterations of cardiac function regulation and 455 
cardiovascular haemodynamia. Although hypothyroidism and hyperthyroidism are 456 
associated with cardiac remodelling, they affect cardiac function and haemodynamic 457 
parameters in a different way.  Our results demonstrated that both thyroid disorders 458 
were associated with hypertrophic remodelling which was and impacted differently on 459 
cardiac function and consequently its adaptation to a hypovolemic state. Additionally, 460 
although the effect of the thyroid disorders on NO production depends on the studied 461 
cardiac chamber, the impact of bleeding is similar in both chambers. Hypovolemia 462 
induced by acute hemorrhage triggered a NOS activation modulating the heart function 463 
to maintain haemodynamic homeostasis. The involvement of NO pathway depended on 464 
a specific NOS isoform, cardiac chamber and thyroid state.  465 
Declaration of interest  466 
Authors declare that there is no conflict of interest that could be perceived as 467 
prejudicing the impartiality of the research reported. 468 
Funding  469 
This work was supported by the University of Buenos Aires Grants 20020110100020.  470 
Acknowledgements  471 
The authors wish to thank Dr. Carlos Libertum from IBYME, Institute-CONICET for 472 
the TSH plasma determinations, Gabriela Pidal from Facultad de Ciencias Veterinarias, 473 
Page 19 of 34
20 
 
Universidad de Buenos Aires, for echocardiographic measurements, Ana Borthwick for 474 
proofreading and language assistance. 475 
 476 
References  477 
Abergel E, Tase M, Bohlender J, Menard J & Chatellier G1995 Which definition for 478 
echocardiographic left ventricular hypertrophy?.  The American journal of cardiology75 479 
498–502. 480 
American journal of physiology. Heart and circulatory physiology277 H8 - H14.  481 
Balaszczuk AM, Arreche ND, Mc Laughlin M, Arranz C & Fellet AL2006 Nitric oxide 482 
synthases are involved in the modulation of cardiovascular adaptation in hemorrhaged 483 
rats. Vascular Pharmacology44(6) 417-26. 484 
Basset A, Blanc J, Messas E, Hagège A & Elghozi JL2001 J Renin-angiotensin system 485 
contribution to cardiac hypertrophy in experimental hyperthyroidism: an 486 
echocardiographic study. Cardiovascular of  Pharmacol37(2) 163-72.  487 
Berk JL, Massoomi N, Hatch C & Goldstein RH 1999 Hypoxia downregulates 488 
tropoelastin gene expression in rat lung fibroblasts by pretranslational mechanisms. 489 
American journal of physiology. Lung cellular and molecular physiology277 L566 - 490 
L572. 491 
Biondi B 2012 Heart failure and thyroid dysfunction. European journal of 492 
endocrinology 609-18. 493 
De Santis V & Singer M 2015 Tissue oxygen tension monitoring of organ perfusion: 494 
rationale, methodologies, and literature. British journal of anaesthesia115 357 - 365. 495 
Elesgaray R, Caniffi C, Ierace DR, Jaime MF, Fellet A, Arranz C & Costa MA2008 496 
Signaling cascade that mediates endothelial nitric oxide synthase activation induced by 497 
atrial natriuretic peptide. Regulatory Peptides 29;151(1-3):130-4. 498 
Page 20 of 34
21 
 
Fellet AL, Arza P, Arreche N, Arranz C & Balaszczuk AM2004 Nitric oxide and 499 
thyroid gland: modulation of cardiovascular function in autonomic-blocked 500 
anaesthetized rats. Experimental  Physiology89(3) 303-12.  501 
Fellet AL, Balaszczuk AM, Arranz C, López-Costa JJ, Boveris A & Bustamante J2006 502 
Autonomic regulation of pacemaker activity: role of heart nitric oxide synthases. 503 
American journal of physiology. Heart and circulatory physiology291(3) H1246-54. 504 
Fellet AL, Boveris AE, T Arranz C & Balaszczuk AM2008 Cardiac mitochondrial nitric 505 
oxide: a regulator of heart rate?. American Journal of Hypertension21(4) 377-81.  506 
Franco MC, Antico Arciuch VG, Peralta JG, Galli S, Levisman D, López LM, Romorini 507 
L, Poderoso JJ & Carreras MC2006 Hypothyroid phenotype is contributed by 508 
mitochondrial complex I inactivation due to translocated neuronal nitric-oxide synthase. 509 
The Journal of biological chemistry281(8) 4779-86. 510 
Fujisawa Y, Mori N, Yube K, Miyanaka H, Miyatake & Abe Y 1999 Role of nitric oxide in 511 
regulation of renal sympathetic nerve activity during hemorrhage in conscious rats. American 512 
Journal of  Physiology Heart Circulation Physiology277 H8-H14. 513 
Fujisawa Y, Mori N, Yube K, Miyanaka H, Miyatake A & Abe Y1999 Role of nitric 514 
oxide in regulation of renal sympathetic nerve activity during hemorrhage in conscious 515 
rats. 516 
Greeley GH Jr, Lipton MA & Kizer JS1982 Serum thyroxine, triiodothyronine, and 517 
TSH levels and TSH release after TRH in aging male and female rats. Endocrine 518 
research communications9(3-4) 169-77. 519 
Grossman W1980 Cardiac hypertrophy: useful adaptation or pathologic process?. The 520 
American journal of medicine69 576–84.  521 
Page 21 of 34
22 
 
Heron MI & Rakusan K1996 Short- and long-term effects of neonatal hypo- and 522 
hyperthyroidism on coronary arterioles in rat. The American journal of physiology271(5 523 
Pt 2) H1746-54. 524 
Lepic E, Burger D, Lu X, Song W & Feng Q2006 Lack of endothelial nitric oxide 525 
synthase decreases cardiomyocyte proliferation and delays cardiac maturation. 526 
American journal of physiology. Cell physiology291  C1240 - C1246. 527 
Moreno C, López A, Llinás MT, Rodríguez F, López-Farré A, Nava E & Salazar 2002 528 
Changes in NOS activity and protein expression during acute and prolonged ANG II 529 
administration. American journal of physiology. Regulatory, integrative and 530 
comparative physiology282 R31 - R37. 531 
Paczwa P & Ganten D 1999 Role of central AT1 and V1 receptors in cardiovascular adaptation 532 
to hemorrhage in SD and renin TGR rats. American Journal of Physiology Heart Circulation 533 
Physiology276 H1918 - H1926. 534 
Rodríguez L, Detomaso F, Braga P, Prendes M, Perosi F, Cernadas G, Balaszczuk A & 535 
Fellet A2015 Neonatal hyperthyroidism on rat heart: interrelation with nitric oxide and 536 
sex. Journal of endocrinological investigation38(6) 685-94.   537 
Sarati LI, Martinez CR, Artés N, Arreche N, López-Costa JJ, Balaszczuk AM & Fellet 538 
AL 2012 Hypothyroidism: age-related influence on cardiovascular nitric oxide system 539 
in rats. Metabolism61(9) 1301-11. 540 
Schadt JC & Hasser EM 2004 Hemodynamic effects of blood loss during a passive response to 541 
a stressor in the conscious rabbit. Regulatory, integrative and comparative physiology286 R373-542 
R380. 543 
Schadt JC & Ludbrook J 1991 Hemodynamic and neurohumoral responses to acute 544 
hypovolemia in conscious mammals. The American journal of physiology260(2 Pt 2) 545 
H305-18. 546 
Page 22 of 34
23 
 
Schmetterer L, Dallinger S, Polak K, Eichler HG & Wolzt M1999 Systemic NO 547 
synthase inhibition blunts the chronotropic, but not the inotropic response to 548 
isoprenaline in man. Nitric Oxide3(3) 209-15. 549 
Sun ZQ, Ojamaa K, Nakamura TY, Artman M, Klein I & Coetzee WA2001 Thyroid 550 
hormone increases pacemaker activity in rat neonatal atrial myocytes. Journal of 551 
molecular and cellular cardiology33(4)811-24.   552 
Vargas-Uricoechea H, Bonelo-Perdomo A & Sierra-Torres CH2014 Effects of thyroid 553 
hormones on the heart. Clínica e investigación en arteriosclerosis26(6) 296-309. 554 
Wang YY, Morimoto S, Du CK, Lu QW, Zhan DY, Tsutsumi T, Ide T, Miwa Y, 555 
Takahashi-Yanaga F & Sasaguri T2010 Up-regulation of type 2 iodothyronine 556 
deiodinase in dilated cardiomyopathy. Cardiovascular Research1 87(4) 636-46. 557 
Wolzt M, Schmetterer L, Ferber W, Artner E, Mensik C, Eichler HG & Krejcy K 1997 558 
Effect of nitric oxide synthase inhibition on renal hemodynamics in humans: reversal by 559 
L-arginine. The American journal of physiology 272(2 Pt 2) F178-82. 560 
 561 
Legends 562 
Figure 1. Left ventricular representative images of M-mode echocardiographic tracing 563 
from euthyroid (panel A), hypothyroid (panel B) and hyperthyroid rats (panel C).  564 
Figure 2. Changes in mean arterial pressure (MAP) and heart rate (HR) during and after 565 
hemorrhage in euthyroid (Eut), hypothyroid (hypo) and hyperthyroid rats (Hyper) 566 
(panels A and C). Changes in MAP and HR during and after hemorrhage in L-NAME 567 
treated  Eut, Hypo and Hyper rats (panels B and D)  .     Eut rats ; ■ hypo rats;▲ Hyper 568 
rats. Points are mean values (error bars represent SEM); n=15/group; *P<0.05 vs. basal 569 
values. 570 
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Figure 3. Total NOS activity in right atria from euthyroid (Eut), hypothyroid (hypo) and 571 
hyperthyroid (Hyper) rats (panel A). The values are mean ± SEM; n=15/group; *P<0.05 572 
vs  Eut rats;  P<0.05 vs  rats without hemorrhage. Representative Western Blots of 573 
eNOS (panel B), iNOS (panel C), nNOS ( panel D), carried out on proteins from Eut, 574 
hypo and Hyper right atria. Histograms illustrate the mean NOS protein values for each 575 
group. All experiments were performed in triplicate. Each blot was normalized with the 576 
expression of the β-actin from the same gels. Data are mean ± SEM.; n=7/group; 577 
*P<0.05 vs Eut rats;  P<0.05 vs rats without hemorrhage. EutH: euthyroid 578 
hemorrhaged rats; hypoH: hypothyroid hemorrhaged rats; HyperH: hyperthyroid 579 
hemorrhaged rats.  580 
Figure 4. Total NOS activity in left ventricle  from euthyroid (Eut), hypothyroid (hypo) 581 
and hyperthyroid (Hyper) rats (panel A). The values are mean ± SEM; n=15/group; 582 
*P<0.05 vs  Eut rats;  P<0.05 vs  rats without hemorrhage. Representative Western 583 
Blots of eNOS (panel B), iNOS (panel C), nNOS (panel  D), carried out on proteins 584 
from Eut, hypo and Hyper left ventricle. Histograms illustrate the mean NOS protein 585 
values for each group. All experiments were performed in triplicate. Each blot was 586 
normalized with the expression of the β-actin from the same gels. Data are mean ± 587 
SEM; n=7/group; *P<0.05 vs  Eut rats;  P<0.05 vs  rats without hemorrhage. EutH: 588 
euthyroid hemorrhaged rats; hypoH: hypothyroid hemorrhaged rats; HyperH: 589 
hyperthyroid hemorrhaged rats.  590 
Figure 5. Total NOS activity in right atria (panel A) and left ventricle (panel B) slices 591 
from euthyroid (Eut), hypothyroid (hypo) and hyperthyroid (Hyper) rats. CZ: 592 
calmidazolium.EutH: euthyroid hemorrhaged rats; EutHCZ: euthyroid hemorrhaged rats 593 
pretreated with CZ; hypoH: hypothyroid hemorrhaged rats; hypoHCZ: hypothyroid 594 
hemorrhaged rats pretreated with CZ; HyperH: hyperthyroid hemorrhaged rats; 595 
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HyperHCZ: hyperthyroid hemorrhaged rats pretreated with CZ. Data are mean ± SEM; 596 
n=7/group; *P<0.05 vs  Eut rats;  P<0.05 vs  rats without hemorrhage.  597 
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Eut (euthyroid rats); Hypo (hypothyroid rats); Hyper (hyperthyroid rats); 
TSH (thyroid-stimulating hormone); T3 (triiodothyronine); T4 (total 
thyroxine); BW (body weight); HR (heart rate); MAP (mean arterial 
pressure); LVIDd (LV internal diameter in diastole); LVIDs (LV internal 
diameter in systole); AWTd (anterior wall thickness in diastole); AWTs 
(anterior wall thickness in systole); PWTd (posterior wall thickness in 
diastole); PWTs (posterior wall thickness in systole); EF (ejection 
fraction); FS (fractional shortening). Data are mean ± SEM; n=15;*P<0.05 
vs. Eut rats. 
Group of 
animals  
Eut Hypo  Hyper  
TSH (ng/ml) 14.75±0.83 35.57±4.35* 5.57±0.03* 
T3 (ng/dl) 1.131±0.123 0.750±0.036* 1.034±0.036 
T4 (ug/ml) 2.475±0.031 1.034±0.036* 3.775±0.270* 
BW (g) 337±12 338±12 298±12 
HR (bpm)  352±15 214±13* 424±15* 
MAP(mmHg) 80±4 70±4 76±2 
LVIDd (mm) 5.40±0.18 5.99±0.19* 4.7±0.10* 
LVIDs (mm) 
AWTd (mm) 










PWTd (mm) 2.10±0.17 1.50±0.10* 2.03±0.15 
PWTs (mm) 2.90±0.08 2.43±0.12* 3.23±0.08 
EF (%) 86±3 83±1* 88±3 
FS (%) 56±2 46±2* 51±2 
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